Patients diagnosed with COVID-19 infection will be offered treatment with Opaganib, 500 mg Q12 hours. Opaganib will be continuously administered for up to 2 weeks, until discharged on room air (if earlier than 2 weeks).
Patients diagnosed with COVID-19 infection by nasopharyngeal viral swab, classified as severe
disease, category 5, by the WHO Ordinal Scale For Clinical Improvement (who require oxygen
support by high flow nasal cannula but do not require mechanical ventilation) at the time of
initiation of therapy will be offered treatment with Opaganib, 500 mg Q12 hours.
Opaganib will be continuously administered for up to 2 weeks, until discharged on room air
(if earlier than 2 weeks), upon voluntary withdrawal is initiated by the patient or when the
physician decides that it is not in the patient's best interest to continue.
Drug: Opaganib
500 mg Q12 hours orally
Inclusion Criteria:
1. Patients with proven COVID-19 infection diagnosed by nasopharyngeal viral swab who
require external oxygen support by high flow nasal cannulas (HFNC) but not mechanical
ventilation.
2. Pneumonia documented by chest x-ray (CXR)
3. The patient or guardian must have signed a written IRB-approved informed consent.
4. A negative pregnancy test (if woman of childbearing potential).
5. Acceptable liver and renal function:
1. Bilirubin ≤ 1.5 times upper limit of normal (CTCAE Grade 2 baseline)
2. AST (SGOT), ALT (SGPT) ≤ 3.0 x upper limit of normal (ULN),
3. Serum creatinine ≤ 1.5 X ULN (CTCAE Grade 1 baseline)
6. Acceptable hematologic status:
1. Absolute neutrophil count ≥1000 cells/mm3
2. Platelet count ≥75,000 (plt/mm3) (CTCAE Grade 1 baseline)
3. Hemoglobin ≥ 9 g/dL
7. Clinically acceptable blood sugar control if diabetic
8. EKG showing no QTc prolongation
Exclusion Criteria:
1. Any co-morbidity that that is considered by the treating investigator as an
unacceptable risk
2. Pregnant or nursing women
3. Unwillingness or inability to comply with procedures required in this protocol.
4. Caution must be exercised in patients who are receiving drugs that were sensitive
substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of
all major CYP450 isozymes that cannot be stopped or replaced with another appropriate
medication or not given for the duration of the clinical study. These patients must be
discussed with the sponsor in order to determine appropriateness for opaganib therapy.
5. Patients who are taking warfarin, apixaban, argatroban or rivaroxaban
6. Patients with QTc prolongation
Shaare Zedek Medical Center
Jerusalem, Israel
Mark L Levitt, MD, Study Director
RedHill Biopharma Limited